You could be reading the full-text of this article now if you...

If you have access to this article through your institution,
you can view this article in

An Eastern Cooperative Oncology Group Phase I-II Pilot Study of Polyriboinosinic-Polyribocytidylic Acid Poly-L-lysine Complex in Patients with Metastatic Malignant Melanoma.

Hawkins, Michael J.; Levin, Mark; Borden, Ernest C.
Journal of Biological Response Modifiers:
Proceedings: Clinical Studies: PDF Only
Abstract

Summary: Sixteen patients with metastatic malignant melanoma were treated with poly(I,C)-LC 5 mg/m2 twice weekly by intravenous injection. No antitumor responses occurred. Fever (frequently >40[degrees]C) and fatigue were dose limiting toxicities. One patient developed a fever of 42.2[degrees]C when poly(I,C)-LC was given on 2 consecutive days. Interferon was consistently detected in the serum 8 h after a single injection of poly(I,C)-LC (median titer 199 U/ml). No enhancement of interferon induction was detected on the second day when poly(I,C)-LC was given on 2 consecutive days.

(C) Lippincott-Raven Publishers.